Alejandro MD - Reneo Pharmaceuticals Chief Officer
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Insider
Alejandro MD is Chief Officer of Reneo Pharmaceuticals
| Age | 63 |
| Phone | 858 283 0280 |
| Web | https://reneopharma.com |
Reneo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3372) % which means that it has lost $0.3372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.54) %, meaning that it created substantial loss on money invested by shareholders. Reneo Pharmaceuticals' management efficiency ratios could be used to measure how well Reneo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Reneo Pharmaceuticals currently holds 973 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Reneo Pharmaceuticals has a current ratio of 15.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reneo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Hicklin | Werewolf Therapeutics | 60 | |
| Mark Adams | Adaptive Biotechnologies Corp | 57 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Lance Laing | Celcuity LLC | 62 | |
| Yvonne MBA | Nkarta Inc | 64 | |
| Thomas Knight | Ginkgo Bioworks Holdings | N/A | |
| Klaus Frueh | Vir Biotechnology | 64 | |
| DSc MSE | Immix Biopharma | 75 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Steven Rice | Vir Biotechnology | 64 | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Igor MD | Celcuity LLC | N/A | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Kyle Piskel | Adaptive Biotechnologies Corp | 40 | |
| Timothy CPA | Werewolf Therapeutics | 66 | |
| Christopher Hite | Royalty Pharma Plc | 56 | |
| Randi MD | Werewolf Therapeutics | 68 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
Management Performance
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 |
Reneo Pharmaceuticals Leadership Team
Elected by the shareholders, the Reneo Pharmaceuticals' board of directors comprises two types of representatives: Reneo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reneo. The board's role is to monitor Reneo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reneo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reneo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Flesher, CEO President | ||
| Alejandro MD, Chief Officer | ||
| Ashley JD, Chief Officer | ||
| Wendy MBA, Consultant | ||
| Vineet Jindal, Consultant | ||
| Michael Cruse, Chief Officer | ||
| Jennifer Lam, Principal Officer | ||
| Lynn Purkins, Senior Development | ||
| Michael Grey, Founder Chairman |
Reneo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reneo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |